Alexis Dormandy will join Oxford Sciences Innovation as chief executive, moving over from Atomico by January 2021 to take over from interim CEO Jim Wilkinson.

Alexis Dormandy, a partner and portfolio company adviser at venture capital firm Atomico, has been appointed chief executive of Oxford Sciences Innovation, the venture fund of University of Oxford.
Dormandy will transition into the job and take the position up full-time in January 2021, when he will replace interim chief executive Jim Wilkinson. The latter will subsequently return to his original position as chief financial officer.
Dormandy studied medicine at University of Oxford before joining consultancy McKinsey as an analyst and moving into executive positions at conglomerate Virgin and telecommunications firm Orange.
His career has also included stints as European chairman of charity Red and managing director and senior adviser at private equity firm Candover & Arle. He joined Atomico in 2016.
Dormandy said: “I could not be more excited to be joining OSI at this point in their journey.
“OSI is building fundamental technology companies capable of tackling some of the world’s toughest problems, and I am thrilled to be a part of this mission, translating breakthrough science into real-world impact.”
Oxford Sciences Innovation has raised £613m in funding to date and helped set up more than 80 spinouts out of the university.
Chris Chambers, chairman of OSI, said: “We have completed a rigorous recruitment process and I am delighted to announce that Alexis Dormandy will be joining OSI as our new CEO.
“Alexis has the perfect expertise and qualities to capitalise on OSI’s success and I look forward to working closely with him. We have made great progress over the last five years and I must thank the team and Jim for their dedication and hard work.
“Now under Alexis’ leadership we will further build on this momentum.”
– Image courtesy of OSI

Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.